세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 보고서(2025년)

Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Global Market Report 2025

US $ 4,490 ￦ 6,521,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,426,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,330,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 규모는 향후 몇 년 동안 연평균 성장률(CAGR) 10.1%로 2029년까지 46억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 치료법 채택 증가, 지원 규제 강화, 임상시험 확대, 정밀 의료 채택 확대, R&D 투자 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 생명공학 기업과 연구기관의 협력 강화, 기술 발전, 암 치료의 발전, 신약 개발의 비약적인 발전 등이 있습니다.

표적 치료제에 대한 수요 증가는 향후 몇 년 동안 윙리스 관련 통합부위(WNT) 신호전달 경로 억제제 시장의 성장을 견인할 것으로 예상됩니다. 표적 치료는 질병 진행에 관여하는 특정 분자나 경로에 초점을 맞추도록 설계되었습니다. 표적 치료의 확대는 부작용을 최소화하면서 특정 유전자 돌연변이를 표적으로 삼아 치료 효과를 향상시키는 정밀 의학에 의해 촉진되고 있으며, WNT 신호전달 경로 억제제는 암세포의 증식 및 전이와 관련된 WNT 경로의 비정상적인 활성화를 억제함으로써 표적 치료에 기여하고 있습니다. 기여합니다. 이를 통해 종양의 진행을 늦추고 치료 성적을 향상시킵니다. 예를 들어, 2024년 7월 미국 유전자세포 치료학회(ASGCT)는 2024년 2분기에 76건의 유전자 치료 임상시험이 시작되었다고 보고했습니다. 그 결과, 표적 치료제에 대한 수요 증가가 WNT 신호전달 경로 억제제 시장의 성장을 뒷받침하고 있습니다.

만성질환의 유병률 증가는 가까운 장래에 WNT 신호전달 경로 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 만성질환은 점진적으로 발병하고 1년 이상 지속되며 일반적으로 지속적인 의학적 관리와 생활습관 개선이 필요한 장기적인 질환입니다. WNT 신호전달 경로 억제제는 세포의 증식, 분화 및 염증을 조절하여 만성질환 관리에 도움을 줄 수 있으며, WNT 신호전달 경로 억제제는 암의 진행을 막고, 섬유화를 억제하며, 신경 보호 효과를 나타낼 수 있습니다. 신경 보호 효과를 가져옵니다. 예를 들어, 미국 비영리단체인 미국암협회는 2022년 1월 미국에서 약 190만 명의 암 환자가 새로 발생하고 60만 9,360명이 암으로 사망할 것으로 예측하고 있으며, 이는 매일 약 1,670명이 사망하는 것과 같습니다. 전 세계적으로 폐암, 전립선암, 대장암, 유방암이 가장 많으며, 새로 진단된 사례의 43%를 차지합니다. 따라서 만성질환의 유병률 증가가 WNT 신호전달 경로 억제제 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 성장률 분석
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 소분자 억제제
• 단클론항체
• 유전자 치료
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 작용기전별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 포큐파인 억제제
• 주름이 진 억제제
• β-카테닌 억제제
• WNT 단백질 억제제
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 개발 단계별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 전임상
• 임상시험
• 승인된 제품
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 암
• 골질환
• 신경질환
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 제약회사
• 조사기관
• 병원
• 진단 검사실
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 저분자 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 포큐파인 억제제
• 탄키라제 억제제
• β-카테닌 억제제
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 단클론항체 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• WNT 리간드 표적 항체
• 후리즈르드 수용체 저해 항체
• 딕 컵(DKK) 항체
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 유전자 치료 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 클러스터화 된 규칙적으로 간격을 둔 짧은 회문 반복 배열(CRISPR)에 기반한 유전자 편집
• RNA 간섭(RNAi) 요법
• 안티센스 올리고뉴클레오티드(ASO)

제7장 지역별·국가별 분석

• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 경쟁 구도
• WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 : 기업 개요
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • STEMCELL Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Abcam Limited
• MedChemExpress LLC
• Enzo Life Sciences International Inc.
• FogPharma Inc.
• Selleck Chemicals LLC
• Santa Cruz Biotechnology, Inc.
• Creative BioMart Inc.
• Redx Pharma plc
• REPROCELL Inc.
• CHEMDIV INC
• PRISM BioLab Co., Ltd.
• Allarity Therapeutics Inc.
• Verastem Oncology Inc.
• OncoMed Pharmaceuticals Inc
• Allied-Bristol Life Sciences LLC

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 2029 : 새로운 기회를 제공하는 국가
• WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 2029 : 새로운 기회를 제공하는 부문
• WNT(Wingless-Related Integration Site) 신호전달 경로 억제제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

A Wingless-related integration site (WNT) signaling pathway inhibitor is a substance or molecule that blocks or suppresses the activity of the WNT signaling pathway, which plays a key role in various biological processes such as cell proliferation, differentiation, migration, and embryonic development.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of WNT signaling pathway inhibitors include small molecule inhibitors, monoclonal antibodies, and gene therapies. Small molecule inhibitors are low molecular weight compounds that modulate disease pathways by targeting key proteins involved in the WNT signaling pathway, thereby regulating processes such as cell proliferation, differentiation, and cancer progression. These inhibitors work through various mechanisms, such as porcupine inhibitors, frizzled inhibitors, B-catenin inhibitors, and WNT protein inhibitors. They are at different stages of development, including preclinical research, clinical trials, and approved products. These inhibitors are applicable to a range of indications, including cancers, bone diseases, and neurological disorders, and are used by various end users, such as pharmaceutical companies, research institutions, hospitals, and diagnostic laboratories.

The wingless-related integration site (WNT) signaling pathway inhibitors market research report is one of a series of new reports from The Business Research Company that provides wingless-related integration site (WNT) signaling pathway inhibitors market statistics, including the wingless-related integration site (WNT) signaling pathway inhibitors industry global market size, regional shares, competitors with the wingless-related integration site (WNT) signaling pathway inhibitors market share, detailed wingless-related integration site (WNT) signaling pathway inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the wingless-related integration site (WNT) signaling pathway inhibitors industry. This wingless-related integration site (WNT) signaling pathway inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The wingless-related integration site (WNT) signaling pathway inhibitor market size has grown rapidly in recent years. It will grow from$2.84 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the rising prevalence of cancer, the increasing occurrence of chronic diseases, advancements in drug development, and the growing prevalence of pulmonary arterial hypertension.

The wingless-related integration site (WNT) signaling pathway inhibitor market size is expected to see rapid growth in the next few years. It will grow to$4.60 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be attributed to the rising adoption of therapies, increasing supportive regulations, expanding clinical trials, the growing adoption of precision medicine, and increased investment in research and development. Key trends expected during this period include greater collaboration between biotech firms and institutions, technological advancements, progress in cancer therapies, and breakthroughs in drug discovery.

The rising demand for targeted therapies is anticipated to drive the growth of the wingless-related integration site (WNT) signaling pathway inhibitor market in the coming years. Targeted therapies are designed to focus on specific molecules or pathways involved in disease progression. The expansion of targeted therapies is fueled by precision medicine, which improves treatment efficacy by targeting specific genetic mutations while minimizing side effects. WNT signaling pathway inhibitors contribute to targeted therapies by blocking the abnormal activation of the WNT pathway, often associated with cancer cell growth and metastasis. By doing so, they slow tumor progression and enhance treatment outcomes. For instance, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a U.S.-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, reflecting a 25% increase compared to the previous quarter. As a result, the growing demand for targeted therapies is supporting the growth of the WNT signaling pathway inhibitor market.

The growing prevalence of chronic diseases is expected to fuel the growth of the WNT signaling pathway inhibitor market in the near future. Chronic diseases are long-lasting conditions that develop gradually, often persist for over a year, and typically require ongoing medical management or lifestyle modifications. A lack of physical activity contributes to weight gain and metabolic issues, increasing the risk of chronic conditions. WNT signaling pathway inhibitors help manage chronic diseases by regulating cell growth, differentiation, and inflammation. They prevent cancer progression, reduce fibrosis, and provide neuroprotective benefits. For example, in January 2022, the American Cancer Society, a U.S.-based nonprofit, projected that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths would occur in the United States, equating to about 1,670 deaths daily. On a global scale, lung, prostate, colorectal, and breast cancers are the most common, accounting for 43% of all newly diagnosed cases. Therefore, the increasing prevalence of chronic diseases is driving the growth of the WNT signaling pathway inhibitor market.

Leading companies in the WNT signaling pathway inhibitor market are focusing on advancing treatments by conducting clinical trials for WNT signaling pathway inhibitors to expand therapeutic options and tackle drug resistance. These clinical trials assess the efficacy and potential benefits of drugs that target the WNT pathway, which plays a key role in cancer development and other diseases. For example, in June 2023, FogPharma, a U.S.-based biopharmaceutical company, announced the initiation of its Phase 1/2 clinical trial for FOG-001, a pioneering TCF-blocking B-catenin inhibitor targeting advanced solid tumors, including colorectal cancer. This open-label, non-randomized study plans to enroll up to 200 patients to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of FOG-001, which disrupts B-catenin-dependent signaling in the Wnt pathway, a key driver of oncogenesis.

Major players in the wingless-related integration site (wnt) signaling pathway inhibitor market are Bayer AG, Novartis AG, Merck KGaA, Eisai Co. Ltd, STEMCELL Technologies Inc., Abcam Limited, MedChemExpress LLC, Enzo Life Sciences International Inc., FogPharma Inc., Selleck Chemicals LLC, Santa Cruz Biotechnology, Inc., Creative BioMart Inc., Redx Pharma plc, REPROCELL Inc., CHEMDIV INC, PRISM BioLab Co., Ltd., Allarity Therapeutics Inc., Verastem Oncology Inc., OncoMed Pharmaceuticals Inc, and Allied-Bristol Life Sciences LLC.

North America was the largest region in the wingless-related integration site (WNT) signaling pathway inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in wingless-related integration site (WNT) signaling pathway inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the wingless-related integration site (WNT) signaling pathway inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The wingless-related integration site (WNT) signaling pathway inhibitor market consists of sales of peptide inhibitors. decoy receptors, fusion proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on wingless-related integration site (wnt) signaling pathway inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for wingless-related integration site (wnt) signaling pathway inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The wingless-related integration site (wnt) signaling pathway inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Small molecule Inhibitors; Monoclonal Antibodies; Gene Therapies
• 2) By Mechanism Of Action: Porcupine Inhibitors; Frizzled Inhibitors; B-Catenin Inhibitors; Wingless-Related Integration Site (WNT)-Protein Inhibitors
• 3) By Stage Of Development: Pre-Clinical; Clinical Trials; Approved Products
• 4) By Indications: Cancers; Bone Diseases; Neurological Disorders
• 5) By End-Users: Pharmaceutical Companies; Research Institutions; Hospitals; Diagnostic Laboratories
• Subsegments:
• 1) By Small Molecule Inhibitors: Porcupine Inhibitors; Tankyrase Inhibitors; B-Catenin Inhibitors
• 2) By Monoclonal Antibodies: Wingless-Related Integration Site (WNT) Ligand-Targeting Antibodies; Frizzled Receptor-Blocking Antibodies; Dickkopf (DKK) Antibodies
• 3) By Gene Therapies: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing; RNA Interference (RNAi) Therapies; Antisense Oligonucleotides (ASOs)
• Companies Mentioned: Bayer AG; Novartis AG; Merck KGaA; Eisai Co. Ltd; STEMCELL Technologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Characteristics

3. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Trends And Strategies

4. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Growth Rate Analysis
• 5.4. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Total Addressable Market (TAM)

6. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Segmentation

• 6.1. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small molecule Inhibitors
• Monoclonal Antibodies
• Gene Therapies
• 6.2. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Porcupine Inhibitors
• Frizzled Inhibitors
• B-Catenin Inhibitors
• Wingless-Related Integration Site (WNT)-Protein Inhibitors
• 6.3. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Clinical
• Clinical Trials
• Approved Products
• 6.4. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancers
• Bone Diseases
• Neurological Disorders
• 6.5. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Institutions
• Hospitals
• Diagnostic Laboratories
• 6.6. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Porcupine Inhibitors
• Tankyrase Inhibitors
• B-Catenin Inhibitors
• 6.7. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wingless-Related Integration Site (WNT) Ligand-Targeting Antibodies
• Frizzled Receptor-Blocking Antibodies
• Dickkopf (DKK) Antibodies
• 6.8. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Sub-Segmentation Of Gene Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing
• RNA Interference (RNAi) Therapies
• Antisense Oligonucleotides (ASOs)

7. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Regional And Country Analysis

• 7.1. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 8.1. Asia-Pacific Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 9.1. China Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 9.2. China Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 10.1. India Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 11.1. Japan Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 11.2. Japan Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 12.1. Australia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 13.1. Indonesia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 14.1. South Korea Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 14.2. South Korea Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 15.1. Western Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 15.2. Western Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 16.1. UK Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 17.1. Germany Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 18.1. France Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 19.1. Italy Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 20.1. Spain Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 21.1. Eastern Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 21.2. Eastern Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 22.1. Russia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 23.1. North America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 23.2. North America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 24.1. USA Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 24.2. USA Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 25.1. Canada Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 25.2. Canada Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 26.1. South America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 26.2. South America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 27.1. Brazil Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 28.1. Middle East Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 28.2. Middle East Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

• 29.1. Africa Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Overview
• 29.2. Africa Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market, Segmentation By Stage Of Development, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Competitive Landscape
• 30.2. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eisai Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. STEMCELL Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Other Major And Innovative Companies

• 31.1. Abcam Limited
• 31.2. MedChemExpress LLC
• 31.3. Enzo Life Sciences International Inc.
• 31.4. FogPharma Inc.
• 31.5. Selleck Chemicals LLC
• 31.6. Santa Cruz Biotechnology, Inc.
• 31.7. Creative BioMart Inc.
• 31.8. Redx Pharma plc
• 31.9. REPROCELL Inc.
• 31.10. CHEMDIV INC
• 31.11. PRISM BioLab Co., Ltd.
• 31.12. Allarity Therapeutics Inc.
• 31.13. Verastem Oncology Inc.
• 31.14. OncoMed Pharmaceuticals Inc
• 31.15. Allied-Bristol Life Sciences LLC

32. Global Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

34. Recent Developments In The Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market

35. Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Wingless-Related Integration Site (WNT) Signaling Pathway Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35035_Wingless_Related_Integration_Site_WNT_Signaling_Pathway_Inhibitor_GMR_2025